Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports

Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is relatively nontoxic in nature and potentiates the antiviral effects of other NRTIs like zidovudine...

Descripción completa

Detalles Bibliográficos
Autores principales: Modak, Dolanchampa, Guha, Subhasish Kamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Drug Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696307/
https://www.ncbi.nlm.nih.gov/pubmed/23833379
http://dx.doi.org/10.4103/0253-7613.111906
_version_ 1782275118810005504
author Modak, Dolanchampa
Guha, Subhasish Kamal
author_facet Modak, Dolanchampa
Guha, Subhasish Kamal
author_sort Modak, Dolanchampa
collection PubMed
description Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is relatively nontoxic in nature and potentiates the antiviral effects of other NRTIs like zidovudine. Although lamivudine is well-tolerated, certain dermatological side effects like severe skin rash may appear. We report a case series of severe skin rashes in four HIV-infected patients, probably due to lamivudine.
format Online
Article
Text
id pubmed-3696307
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36963072013-07-05 Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports Modak, Dolanchampa Guha, Subhasish Kamal Indian J Pharmacol Drug Watch Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is relatively nontoxic in nature and potentiates the antiviral effects of other NRTIs like zidovudine. Although lamivudine is well-tolerated, certain dermatological side effects like severe skin rash may appear. We report a case series of severe skin rashes in four HIV-infected patients, probably due to lamivudine. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3696307/ /pubmed/23833379 http://dx.doi.org/10.4103/0253-7613.111906 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Drug Watch
Modak, Dolanchampa
Guha, Subhasish Kamal
Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports
title Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports
title_full Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports
title_fullStr Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports
title_full_unstemmed Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports
title_short Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports
title_sort severe skin rash with lamivudine in hiv infected patients: some unusual case reports
topic Drug Watch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696307/
https://www.ncbi.nlm.nih.gov/pubmed/23833379
http://dx.doi.org/10.4103/0253-7613.111906
work_keys_str_mv AT modakdolanchampa severeskinrashwithlamivudineinhivinfectedpatientssomeunusualcasereports
AT guhasubhasishkamal severeskinrashwithlamivudineinhivinfectedpatientssomeunusualcasereports

Ejemplares similares